Skip to main content

Table 2 Ongoing phase 3 clinical trials for advanced stage or unresectable hepatocellular carcinoma

From: Emerging agents and regimens for hepatocellular carcinoma

Trial Lines Arms identifier Sponsor
IMbrave150 First line Atezolizumab + bevacizumab vs sorafenib NCT03434379 Roche
  First line Tislelizumab vs sorafenib NCT03412773 BeiGene
ZGDH3 First line Donafenib vs sorafenib NCT02645981 Zelgen
HIMALAYA First line Durvalumab or durvalumab + tremelimumab vs sorafenib NCT03298451 AstraZeneca
LEAP-002 First line Lenvatinib + pembrolizumab vs lenvatinib NCT03713593 MSD + Eisai
COSMIC-312 First line Cabozantinib + atezolizumab vs sorafenib vs cabozantinib NCT03755791 Exelixis
SHR-1210-III-310 First line Camrelizumab + apatinib vs sorafenib NCT03764293 Hengrui
ORIENT-32 First line Sintilimab + IBI305 vs sorafenib NCT03794440 Innovent
PHOCUS First line Pexa-Vec followed by sorafenib vs sorafenib NCT02562755 SillaJen
KEYNOTE-394 Second line Pembrolizumab vs placebo in Asian pts. NCT03062358 MSD
AHELP Second line Apatinib vs placebo NCT02329860 Hengrui